Shares of Gland Pharma gained about 5 percent on February 25, clocking its best day in 16 weeks, ahead of its investor meet on Feb 27-28 during the analyst day with Emkay and BoB Capital.

As a result of these revisions, Nomura has reduced its earnings per share (EPS) forecasts for Gland Pharma for fiscal years 2025, 2026, and 2027 by 4.7%, 4.6%, and 4.0%, respectively. The report ...

Discover top medications for 'treating Adrenal Gland Disorders'? This page compiles essential information on generic and brand-name drugs specifically used for Adrenal Gland Disorders treatment ...

Gland Pharma shares fell by 4.5% to their intraday low of Rs 1,452 on the BSE after the company reported a 7% year-on-year (YoY) increase in net profit to Rs 205 crore for Q3FY25, compared to Rs ...